In the latest trading session, 1.96 million NovoCure Ltd (NASDAQ:NVCR) shares changed hands as the company’s beta touched 0.73. With the company’s most recent per share price at $31.37 changing hands around $1.52 or 5.08% at last look, the market valuation stands at $3.39B. NVCR’s current price is a discount, trading about -0.64% off its 52-week high of $31.57. The share price had its 52-week low at $11.66, which suggests the last value was 62.83% up since then. When we look at NovoCure Ltd’s average trading volume, we note the 10-day average is 1.94 million shares, with the 3-month average coming to 1.22 million.
Analysts gave the NovoCure Ltd (NVCR) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.57. If we narrow down to specifics, the data shows that 1 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended NVCR as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. NovoCure Ltd’s EPS for the current quarter is expected to be -0.36.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NovoCure Ltd (NASDAQ:NVCR) trade information
Instantly NVCR is in green as seen in intraday trades today. With action 67.02%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 110.09%, with the 5-day performance at 67.02% in the green. However, in the 30-day time frame, NovoCure Ltd (NASDAQ:NVCR) is 93.86% up. Looking at the short shares, we see there were 5.67 million shares sold at short interest cover period of 4.31 days.
The consensus price target for the stock as assigned by Wall Street analysts is 36, meaning bulls need an upside of 12.86% from its recent market value. According to analyst projections, NVCR’s forecast low is 28 with 200 as the target high. To hit the forecast high, the stock’s price needs a -537.55% plunge from its current level, while the stock would need to tank 10.74% for it to hit the projected low.
NovoCure Ltd (NVCR) estimates and forecasts
Data shows that the NovoCure Ltd share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 37.45% over the past 6 months, a 32.82% in annual growth rate that is considerably higher than the industry average of 17.60%. Year-over-year growth is forecast to reach 17.20% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 153.05M. 2 analysts are of the opinion that NovoCure Ltd’s revenue for the current quarter will be 154.99M. The company’s revenue for the corresponding quarters a year ago was 133.78M and 138.5M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 14.40%. The estimates for the next quarter sales put growth at 11.91%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -22.97%. The 2024 estimates are for NovoCure Ltd earnings to increase by 32.61%.
NVCR Dividends
NovoCure Ltd is expected to release its next quarterly earnings report in January.
NovoCure Ltd (NASDAQ:NVCR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.26% of NovoCure Ltd shares while 87.31% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 96.21%. There are 87.31% institutions holding the NovoCure Ltd stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 15.0482% of the shares, roughly 16.14 million NVCR shares worth $276.51 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 11.3106% or 12.13 million shares worth $207.83 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Fidelity Growth Company Fund and Smallcap World Fund. With 5.3 shares estimated at $162.25 million under it, the former controlled 4.90% of total outstanding shares. On the other hand, Smallcap World Fund held about 4.18% of the shares, roughly 4.52 shares worth around $138.51 million.